tiprankstipranks
Advertisement
Advertisement

Novo Nordisk Advances DKK 15 Billion Share Buyback Programme in February 2026

Story Highlights
  • Novo Nordisk has launched a year-long DKK 15 billion B-share repurchase to bolster capital efficiency and shareholder returns.
  • By 13 February 2026, the company had bought 1.75 million B shares, raising treasury holdings to 0.4 percent of capital.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Novo Nordisk Advances DKK 15 Billion Share Buyback Programme in February 2026

Meet Samuel – Your Personal Investing Prophet

Novo Nordisk ( (NVO) ) has provided an update.

Novo Nordisk has stepped up its capital return efforts with a new share repurchase initiative launched on 4 February 2026 under EU Safe Harbour rules. The programme, part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months, aims to optimise the group’s capital structure and support shareholder value.

Between 9 and 13 February 2026, the company repurchased 1,000,000 B shares, lifting total buybacks since 4 February to 1,750,000 shares at an average price of DKK 305.03 and a value of DKK 533.8 million. After incentive-related share transfers and the latest buybacks, Novo Nordisk held 19,139,799 B shares as treasury stock, or about 0.4% of its share capital, underscoring ongoing balance-sheet flexibility and sustained confidence in its long-term earnings power.

The most recent analyst rating on (NVO) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.

The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The group focuses on defeating serious chronic diseases, building on a long heritage in diabetes, and markets its medicines in about 170 countries through a workforce of roughly 68,800 employees.

Average Trading Volume: 21,788,699

Technical Sentiment Signal: Sell

Current Market Cap: $218.9B

Learn more about NVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1